Influence of Disease-Modifying Therapy on the Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis.
Arielle Abovich, Marianna Fontana, Brian Claggett et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the impact of concomitant disease-modifying therapies on the efficacy of vutrisiran in 654 patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The study found no significant modification of vutrisiran's treatment effect on all-cause mortality and recurrent cardiovascular events by the use of tafamidis or other heart failure medications, with P-interaction values indicating no statistical significance across various therapies.
Key findings
- 40% of participants were receiving tafamidis at baseline.
- 77% of participants were on at least one heart failure medication.
- No significant treatment effect modification by concomitant therapies was observed (P-interaction values ranged from 0.59 to 0.95).
Why it matters
Understanding the interaction between disease-modifying therapies and new treatments like vutrisiran is crucial for optimizing patient management in ATTR-CM. This study suggests that vutrisiran's efficacy remains consistent regardless of concurrent heart failure therapies.